The efficiency of peptide immunotherapy for respiratory allergy

References

• Noon L, Cantab BC, Eng FR. Prophylactic inoculation against hay fever. Lancet. 1911;177:1572–1573.
   Google Scholar
• Incorvaia C, Frati F. One century of allergen-specific immunotherapy for respiratory allergy. Immunotherapy. 2011;3:629–635.
   PubMed Web of Science ®Google Scholar
• Frankland A, Augustin R. Prophylaxis of summer hay fever and asthma: a controlled trial comparing crude grass pollen extract with the isolated main protein components. Lancet. 1954;266;:1055–1058.
   PubMed Web of Science ®Google Scholar
• Calderon MA, Alves B, Jacobson M, et al. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev. 2007;1:CD001936.
   PubMed Web of Science ®Google Scholar
• Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev. 2010;4(8):CD001186.
   Google Scholar
• Boyle RJ, Elremeli M, Hockenhull J, et al. Venom immunotherapy for preventing allergic reactions to insect stings. Cochrane Database Syst Rev. 2012;10:CD008838.
   PubMedGoogle Scholar
• Jutel M, Akdis CA. Immunological mechanisms of allergen-specific immunotherapy. Allergy. 2011;66:725–732.
   PubMed Web of Science ®Google Scholar
• Akdis M, Akdis CA. Therapeutic manipulation of immune tolerance in allergic disease. Nat Rev Drug Discov. 2009;8:645–660.
   PubMed Web of Science ®Google Scholar
• Senti G, Graf N, Haug S, et al. Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy. J Allergy Clin Immunol. 2009;124:997–1002.
   PubMed Web of Science ®Google Scholar
• Senti G, Prinz Vavricka BM, Erdmann I, et al. Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc Natl Acad Sci USA. 2008;105:17908–17912.
   PubMed Web of Science ®Google Scholar
• Zuberbier T, Bachert C, Bousquet PJ, et al. GA2LEN/EAACI pocket guide for allergen-specific immunotherapy for allergic rhinitis and asthma. Allergy. 2010;65:1525–1533.
   PubMed Web of Science ®Google Scholar
• Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol. 2011;127(1 Suppl):S1–55.
   PubMed Web of Science ®Google Scholar
• Jutel M, Agache I, Bonini S, et al. International consensus on allergy immunotherapy. J Allergy Clin Immunol. 2015;136:556–568.
   PubMed Web of Science ®Google Scholar
• Walker SM, Durham SR, Till SJ, et al. British Society for Allergy and Clinical Immunology. Immunotherapy for Allergic Rhinitis. Clin Exp Allergy. 2011;41:1177–1200.
   PubMed Web of Science ®Google Scholar
• Canonica GW, Bousquet J, Casale T, et al. Sub-lingual immunotherapy: world allergy organization position paper 2009. World Allergy Organ J. 2009;2(11):2332–2381.
   Google Scholar
• Akdis M. New treatments for allergen immunotherapy. World Allergy Organ J. 2014;7(1):23.
   PubMedGoogle Scholar
• Yssel H, Fasler S, Lamb J, et al. Induction of non-responsiveness in human allergen-specific type 2 T helper cells. Curr Opin Immunol. 1994;6(6):847–852.
   PubMed Web of Science ®Google Scholar
• Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy: multiple suppressor factors at work in immune tolerance to allergens. J Allergy Clin Immunol. 2014;133:621–631.
   PubMed Web of Science ®Google Scholar
• Tarzi M, Klunker S, Texier C, et al. Induction of interleukin-10 and suppressor of cytokine signalling-3 gene expression following peptide immunotherapy. Clin Exp Allergy. 2006;36(4):465–474.
   PubMed Web of Science ®Google Scholar
• Alexander C, Ying S, B Kay A, et al. Fel d 1-derived T cell peptide therapy induces recruitment of CD4+ CD25+; CD4+ interferon-gamma+ T helper type 1 cells to sites of allergen-induced late-phase skin reactions in cat-allergic subjects. Clin Exp Allergy. 2005;35(1):52–58.
   PubMed Web of Science ®Google Scholar
• Smith TR, Alexander C, Kay AB, et al. Cat allergen peptide immunotherapy reduces CD4+ T cell responses to cat allergen but does not alter suppression by CD4+ CD25+ T cells: a double-blind placebo-controlled study. Allergy. 2004;59(10):1097–1101.
   PubMed Web of Science ®Google Scholar
• Verhoef A, Alexander C, Kay AB, et al. T cell epitope immunotherapy induces a CD4+ T cell population with regulatory activity. PLoS Med. 2005;2(3):e78.
   PubMed Web of Science ®Google Scholar
• Campbell JD, Buckland KF, McMillan SJ, et al. Peptide immunotherapy in allergic asthma generates IL-10-dependent immunological tolerance associated with linked epitope suppression. J Exp Med. 2009;206(7):1535–1544.
   PubMed Web of Science ®Google Scholar
• Moldaver DM, Bharhani MS, Wattie JN, et al. Amelioration of ovalbumin-induced allergic airway disease following Der p 1 peptide immunotherapy is not associated with induction of IL-35. Mucosal Immunol. 2014;7(2):379–390.
   PubMed Web of Science ®Google Scholar
• Müller U, Akdis CA, Fricker M, et al. Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol. 1998;101(6 Pt 1):747–754.
   PubMed Web of Science ®Google Scholar
• Moldaver D, Larché M. Immunotherapy with peptides. Allergy. 2011;66(6):784–791.
   PubMed Web of Science ®Google Scholar
• O’Hehir RE, Prickett SR, Rolland JM. T-cell epitope peptide therapy for allergic diseases. Curr Allergy Asthma Rep. 2016;16:14.
   PubMed Web of Science ®Google Scholar
• Hoyne GF, O’Hehir RE, Wraith DC, et al. Inhibition of T cell and antibody responses to house dust mite allergen by inhalation of the dominant T cell epitope in naive and sensitized mice. J Exp Med. 1993;178(5):1783–1788.
   PubMed Web of Science ®Google Scholar
• Bauer L, Bohle B, Jahn-Schmid B, et al. Modulation of the allergic immune response in BALB/c mice by subcutaneous injection of high doses of the dominant T cell epitope from the major birch pollen allergen Bet v 1. Clin Exp Immunol. 1997;107(3):536–541.
   PubMed Web of Science ®Google Scholar
• Briner TJ, Kuo MC, Keating KM, et al. Peripheral T-cell tolerance induced in naive and primed mice by subcutaneous injection of peptides from the major cat allergen Fel d I. Proc Natl Acad Sci USA. 1993;90:7608–7612.
   PubMed Web of Science ®Google Scholar
• Yoshitomi T, Nakagami Y, Hirahara K, et al. Intraoral administration of a T-cell epitope peptide induces immunological tolerance in Cry j 2-sensitized mice. J Pept Sci. 2007;13:499–503.
   PubMed Web of Science ®Google Scholar
• Hirahara K, Saito S, Serizawa N, et al. Oral administration of a dominant T- cell determinant peptide inhibits allergen-specific TH1 and TH2 cell responses in Cry j 2-primed mice. J Allergy Clin Immunol. 1998;102:961–967.
   PubMed Web of Science ®Google Scholar
• Till SJ, Raynsford EJ, Reynolds CJ, et al. Peptide-induced immune regulation by a promiscuous and immunodominant CD4T-cell epitope of Timothy grass pollen: a role of Cbl-b and Itch in regulation. Thorax. 2014;69:335–345.
   PubMed Web of Science ®Google Scholar
• Marazuela EG, Rodriguez R, Fernandez-Garcia H, et al. Intranasal immunization with a dominant T-cell epitope peptide of a major allergen of olive pollen prevents mice from sensitization to the whole allergen. Mol Immunol. 2008;45:438–445.
   PubMed Web of Science ®Google Scholar
• Norman PS, Ohman JL Jr, Long AA, et al. Treatment of cat allergy with T-cell reactive peptides. Am J Respir Crit Care Med. 1996;154(6 Pt 1):1623–1628.
   PubMed Web of Science ®Google Scholar
• Simons FE1, Imada M, Li Y, et al. Fel d 1 peptides: effect on skin tests and cytokine synthesis in cat-allergic human subjects. Int Immunol. 1996;8(12):1937–1945.
   PubMed Web of Science ®Google Scholar
• Pene J, Desroches A, Paradis L, et al. Immunotherapy with Fel d 1 peptides decreases IL-4 release by peripheral blood T cells of patients allergic to cats. J Allergy Clin Immunol. 1998;102:571–578.
   PubMed Web of Science ®Google Scholar
• Maguire P, Nicodemus C, Robinson D, et al. The safety and efficacy of ALLERVAX CAT in cat allergic patients. Clin Immunol. 1999;93:222–231.
   PubMed Web of Science ®Google Scholar
• Larché M. T-cell epitope-based allergy vaccines. Curr Top Microbiol Immunol. 2011;352:107–119.
   PubMed Web of Science ®Google Scholar
• Larché M, Moldavar D. Immunotherapy with peptides. Allergy. 2011;66:784–791.
   PubMed Web of Science ®Google Scholar
• Worm M, Lee HH, Kleine-Tebbe J, et al. Development and preliminary evaluation of a peptide immunotherapy vaccine for cat allergy. J Allergy Clin Immunol. 2011;127:89–97.
   PubMed Web of Science ®Google Scholar
• Oldfield W, Larché M, Kay AB. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet. 2002;360:47–53.
   PubMed Web of Science ®Google Scholar
• Worm M, Patel D, Creticos PS. Cat peptide antigen desensitisation for treating cat allergic rhinoconjunctivitis. Expert Opin Investig Drugs. 2013;22:1347–1357.
   PubMed Web of Science ®Google Scholar
• Patel D, Couroux P, Hickey P, et al. Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo-controlled study. J Allergy Clin Immunol. 2013;131(1):103–109.
   PubMed Web of Science ®Google Scholar
• Couroux P1, Patel D, Armstrong K, et al. Fel d 1-derived synthetic peptide immuno-regulatory epitopes show a long-term treatment effect in cat allergic subjects. Clin Exp Allergy. 2015;45(5):974–981.
   PubMed Web of Science ®Google Scholar
• Hafner RP, Couroux P, Armstrong K, et al. Persistent treatment effect achieved at one year after four doses of Der p derived synthetic peptide immuno-regulatory epitopes in an exposure chamber model of house dust mite allergy. J Allergy Clin Immunol. 2014;133:AB289.
   Google Scholar
• Ellis AK, Frankish CW, Armstrong K, et al. Treatment with synthetic peptide immuno-regulatory epitopes derived from grass allergens leads to a substantial reduction in grass allergy symptoms in the environmental exposure unit. J Allergy Clin Immunol. 2014;133:AB290.
   Google Scholar
• Creticos PS. Advances in synthetic peptide immuno-regulatory epitopes. World Allergy Organ J. 2014;7(1):30.
   PubMedGoogle Scholar
• Haselden BM, Larché M, Meng Q, et al. Late asthmatic reactions provoked by intradermal injection of T-cell peptide epitopes are not associated with bronchial mucosal infiltration of eosinophils or T(H)2-type cells or with elevated concentrations of histamine or eicosanoids in bronchoalveolar fluid. J Allergy Clin Immunol. 2001;108:394–401.
   PubMed Web of Science ®Google Scholar
• Marth K, Focke-Tejkl M, Lupinek C, et al. Allergen peptides, recombinant allergens and hypoallergens for allergen-specific immunotherapy. Curr Treat Options Allergy. 2014;1:91–106.
   PubMedGoogle Scholar
• Prickett SR, Rolland JM, O’Hehir RE. Immunoregulatory T cell epitope peptides: the new frontier in allergy therapy. Clin Exp Allergy. 2015;45(6):1015–1026.
   PubMed Web of Science ®Google Scholar
• Larché M. Mechanisms of peptide immunotherapy in allergic airways disease. Ann Am Thorac Soc. 2014;11(Suppl 5):S292–6.
   PubMedGoogle Scholar
• Circassia Ltd. A double-blind, randomized, placebo-controlled, multi-centre field study to assess the efficacy and safety of Cat-PAD peptide immunotherapy in cat allergic subjects [Internet; cited 2015 Nov 10]. Available from: http://clinicaltrials.gov/show/NCT01620762. NML identifier NCT0 1620762.
   Google Scholar
• Hafner RP, Salapatek AM, Patel D, et al. Validation of peptide immunotherapy as a new approach in the treatment of allergic rhinoconjunctivitis: the clinical benefits of treatment with Amb a 1-derived Tcell epitopes. J Allergy Clin Immunol. 2012;(Suppl 2):AB368.
   Google Scholar
• Larché M, Hickey P, Hebert J, et al. Safety and tolerability of escalating doses of HDM peptide antigen desensitization. J Allergy Clin Immunol. 2013;(Suppl 2):AB37.
   Google Scholar